You are here

Ebola’s Evolutionary Roots More Ancient Than Previously Thought, Study Finds

Ebola and Marburg shared common ancestor millions of years ago

A new study is helping to rewrite Ebola’s family history.

The research shows that filoviruses — a family to which Ebola and its similarly lethal relative, Marburg, belong — are at least 16 to 23 million years old.

Filoviruses likely existed in the Miocene Epoch, and at that time, the evolutionary lines leading to Ebola and Marburg had already diverged, the study concludes.

The research was published in the journal PeerJ in September. It adds to scientists’ developing knowledge about known filoviruses, which experts once believed came into being some 10,000 years ago, coinciding with the rise of agriculture. The new study pushes back the family’s age to the time when great apes arose.

“Filoviruses are far more ancient than previously thought,” said lead researcher Derek Taylor, PhD, of the University at Buffalo. “These things have been interacting with mammals for a long time, several million years.”

According to the article, knowing more about Ebola and Marburg’s comparative evolution could “affect design of vaccines and programs that identify emerging pathogens.”

The research does not address the age of the modern-day Ebolavirus. Instead, it shows that Ebola and Marburg are each members of ancient evolutionary lines, and that these two viruses last shared a common ancestor sometime before 16 to 23 million years ago.

Taylor and co-author Jeremy Bruenn, PhD, research viral “fossil genes” — chunks of genetic material that animals and other organisms acquire from viruses during infection.

In the new study, the authors report finding remnants of filovirus-like genes in various rodents. One fossil gene, called VP35, appeared in the same spot in the genomes of four different rodent species: two hamsters and two voles. This meant the material was likely acquired in or before the Miocene Epoch, prior to when those rodents evolved into distinct species some 16 to 23 million years ago.

In other words, it appears that the known filovirus family is at least as old as the common ancestor of hamsters and voles.

“These rodents have billions of base pairs in their genomes, so the odds of a viral gene inserting itself at the same position in different species at different times are very small,” Taylor said. “It’s likely that the insertion was present in the common ancestor of these rodents.”

The genetic material in the VP35 fossil was more closely related to Ebola than to Marburg, indicating that the lines leading to these viruses had already begun diverging from each other in the Miocene.

The new study builds on Taylor’s previous work with Bruenn and other biologists, which used viral fossil genes to estimate that the entire family of filoviruses was more than 10 million years old. However, those studies used fossil genes only distantly related to Ebola and Marburg, which prevented the researchers from drawing conclusions about the age of those two viral lines.

The current PeerJ publication fills this viral “fossil gap,” enabling the scientists to explore Ebola’s historical relationship with Marburg.

The first Ebola outbreak in humans occurred in 1976, and scientists still know little about the virus’ history. The same dearth of information applies to Marburg, which was recognized in humans in 1967 and was implicated in the death of a Ugandan health worker this month.

Understanding the virus’ ancient past could aid in disease prevention, Taylor said. He noted that if a researcher were trying to create a single vaccine effective against both Ebola and Marburg, it could be helpful to know that their evolutionary lineages diverged so long ago.

Knowing more about filoviruses in general could provide insight into which host species might serve as “reservoirs” that harbor undiscovered pathogens related to Ebola and Marburg, Taylor said.

Source: University at Buffalo; October 24, 2014.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
National Statistics Report Factors In Race, Ethnicity for the First Time